Hyeon-Young Kim

Hyeon-Young received her Master’s degree in Pharmaceutical Sciences from Seoul National University, South Korea, in 2024. Her research focused developing a fusion Granzyme B protein, secreted by cytotoxic immune cells, to overcome cancer resistance driven by overexpressed anti-apoptotic proteins such as Serpin B9 and Bcl-2. In November 2024, funded by a Korean Research Foundation scholarship, she began exploring strategies to sensitize tyrosine kinase-resistant B-cell malignancies. She is excited to contribute to meaningful advancements in overcoming cancer resistance as part of the Müschen Lab.